GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cantargia AB (OSTO:CANTA) » Definitions » YoY Rev. per Sh. Growth

Cantargia AB (OSTO:CANTA) YoY Rev. per Sh. Growth : 0.00% (As of Sep. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Cantargia AB YoY Rev. per Sh. Growth?

YoY Rev. per Sh. Growth is the percentage change of Revenue per Share over the past twelve months. Cantargia AB's YoY Rev. per Sh. Growth for the quarter that ended in Sep. 2024 was 0.00%.

Cantargia AB's Revenue per Share for the three months ended in Sep. 2024 was kr0.00.

Cantargia AB YoY Rev. per Sh. Growth Historical Data

The historical data trend for Cantargia AB's YoY Rev. per Sh. Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cantargia AB YoY Rev. per Sh. Growth Chart

Cantargia AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
YoY Rev. per Sh. Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Cantargia AB Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
YoY Rev. per Sh. Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Cantargia AB YoY Rev. per Sh. Growth Calculation

YoY Rev. per Sh. Growth is the percentage change of Revenue per Share over the past twelve months.

Cantargia AB's YoY Rev. per Sh. Growth for the fiscal year that ended in Dec. 2023 is calculated as:

YoY Rev. per Sh. Growth (A: Dec. 2023 )
=(Revenue per Share (A: Dec. 2023 )-Revenue per Share (A: Dec. 2022 ))/ | Revenue per Share (A: Dec. 2022 ) |
=(0-0)/ | 0 |
=N/A %

Cantargia AB's YoY Rev. per Sh. Growth for the quarter that ended in Sep. 2024 is calculated as:

YoY Rev. per Sh. Growth (Q: Sep. 2024 )
=(Revenue per Share (Q: Sep. 2024 )-Revenue per Share (Q: Sep. 2023 )) / | Revenue per Share (Q: Sep. 2023 )) |
=(0-0)/ | 0 |
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cantargia AB YoY Rev. per Sh. Growth Related Terms

Thank you for viewing the detailed overview of Cantargia AB's YoY Rev. per Sh. Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

Cantargia AB Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cantargia AB (OSTO:CANTA) » Definitions » YoY Rev. per Sh. Growth
Comparable Companies
OSTO:DMYD B OSTO:XBRANE XSAT:CURAS OSTO:ONCO OSTO:SYNACT OSTO:ITECH OSTO:INIT OSTO:IVACC OSTO:INDEX OSTO:KDEV OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
7V3:Germany
Address
Scheelevagen 27, Lund, SWE, SE-223 63
Website
https://www.cantargia.com
Cantargia AB is engaged in the development of products used in the treatment of cancer. It has developed specific antibodies against IL1RAP to treat serious, life-threatening diseases. The company's first product candidate, CAN04, has also been designed to treat different forms of cancer, with the initial focus on the treatment of non-small cell lung cancer and pancreatic cancer. The CAN10 project covers a disease segment that complements nadunolimab and diversifies Cantargia's project portfolio.

Cantargia AB Headlines

No Headlines